ATE360642T1 - Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 - Google Patents

Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4

Info

Publication number
ATE360642T1
ATE360642T1 AT03704793T AT03704793T ATE360642T1 AT E360642 T1 ATE360642 T1 AT E360642T1 AT 03704793 T AT03704793 T AT 03704793T AT 03704793 T AT03704793 T AT 03704793T AT E360642 T1 ATE360642 T1 AT E360642T1
Authority
AT
Austria
Prior art keywords
seq
amino acid
acid sequence
sequence shown
mhc class
Prior art date
Application number
AT03704793T
Other languages
English (en)
Inventor
Miles Carroll
Susan Kingsman
Irina Redchenko
Original Assignee
Oxford Biomedica Ltd
Idm S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd, Idm S A filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE360642T1 publication Critical patent/ATE360642T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03704793T 2002-02-13 2003-02-13 Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 ATE360642T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0203419.7A GB0203419D0 (en) 2002-02-13 2002-02-13 Peptide

Publications (1)

Publication Number Publication Date
ATE360642T1 true ATE360642T1 (de) 2007-05-15

Family

ID=9931004

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03704793T ATE360642T1 (de) 2002-02-13 2003-02-13 Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4

Country Status (9)

Country Link
US (3) US7575916B2 (de)
EP (1) EP1476463B1 (de)
JP (1) JP4533630B2 (de)
AT (1) ATE360642T1 (de)
AU (1) AU2003207321B2 (de)
CA (1) CA2476165A1 (de)
DE (1) DE60313437T2 (de)
GB (1) GB0203419D0 (de)
WO (1) WO2003068816A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
EP1578371A4 (de) * 2002-08-19 2009-05-20 Genentech Inc Zusammensetzungen und verfahren für die tumor-diagnose und behandlung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
JP4926168B2 (ja) * 2005-05-13 2012-05-09 オックスフォード バイオメディカ（ユーケー）リミテッド ペプチド
GB0520067D0 (en) * 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
WO2007062371A2 (en) * 2005-11-23 2007-05-31 University Of Maryland, Baltimore Live vector vaccine and uses thereof
PT1994055E (pt) * 2006-03-10 2014-09-15 Wyeth Llc Anticorpos anti-5t4 e utilizações dos mesmos
WO2008059252A2 (en) * 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
EP2313784B1 (de) 2008-07-15 2015-02-18 Oxford BioMedica (UK) Limited Immuntherapieverfahren
GB201807932D0 (en) * 2018-05-16 2018-06-27 Redchenko Irina Compositions and methods for inducing an immune response
FR3119325B1 (fr) 2021-01-29 2023-08-11 Renault Jean Yves Compositions liposomales orales

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570940B2 (en) 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
GB8305967D0 (en) 1983-03-04 1983-04-07 Univ Liverpool Material for treatment of spontaneous abortions
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
WO1989007947A1 (en) 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
IL92629A0 (en) 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
BR9106826A (pt) 1990-08-13 1994-01-25 Isis Pharmaceuticals Inc Oligonucleotideo ou analogo de oligonucleotideo,processo para modular a producao de uma proteina por um organismo,para tratar um organismo e processos para sintetizar:9(2'-desoxi-2'-substituido-beta-d-ribofuranosil)-guanina e g('-desoxi-2'-fluor-beta-d-ribofuranosil)-guanina
WO2001000225A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
WO2000029428A2 (en) * 1998-11-18 2000-05-25 Oxford Biomedica (Uk) Limited 5t4 tumour-associated antigen for use in tumour immunotherapy
AU747609B2 (en) 1997-09-23 2002-05-16 Oxford Biomedica (Uk) Limited Expression of genes in hematopoietic stem cells in hischaemic conditions
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
GB2370573A (en) 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
EP1347994A2 (de) 2000-11-13 2003-10-01 Oxford Biomedica (UK) Limited Tumorassoziiertes antigen 5t4 von hunden und katzen
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide

Also Published As

Publication number Publication date
JP2006500903A (ja) 2006-01-12
AU2003207321A1 (en) 2003-09-04
GB0203419D0 (en) 2002-04-03
EP1476463A1 (de) 2004-11-17
US7888115B2 (en) 2011-02-15
CA2476165A1 (en) 2003-08-21
US7575916B2 (en) 2009-08-18
US20100086995A1 (en) 2010-04-08
DE60313437T2 (de) 2008-01-03
US20050123918A1 (en) 2005-06-09
JP4533630B2 (ja) 2010-09-01
AU2003207321B2 (en) 2009-01-29
DE60313437D1 (de) 2007-06-06
EP1476463B1 (de) 2007-04-25
US20110165668A1 (en) 2011-07-07
WO2003068816A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
AU768002B2 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
ATE418562T1 (de) Ctl epitope des epstein-barr virus
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
MXPA05014152A (es) Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
ATE466879T1 (de) 5t4-antigen-peptidepitope der mhc klasse ii
ATE366582T1 (de) Optimierte minigene und dadurch kodierte peptide
JP2021042247A (ja) Ａ群レンサ球菌ワクチン
PT1417222E (pt) Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante
GEP20063774B (en) Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
CN101402674A (zh) 附睾蛋白酶抑制剂的功能肽段及应用
Maillère et al. Immunogenicity of a disulphide-containing neurotoxin: presentation to T-cells requires a reduction step
EP2193804A3 (de) Rekombinantes Adenylat-Cyclase-Toxin von Bordetella induziert T-Zell-Antworten gegen tumorale Antigene
WO2004022092A3 (en) Flagellin peptides as adjuvants for vaccines
JP2007511534A5 (de)
EP1557466A4 (de) Tumorantigenprotein und dessen verwendung
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide
Purton et al. Enhancing T cell memory: IL-7 as an adjuvant to boost memory T-cell generation
EP2277918A3 (de) Vom Tumorantigen 5t4 abgeleitete Mhc-Klasse-I- und II-Peptidantigene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1476463

Country of ref document: EP